Elranatamab Injection 76?mg/1.9?mL/Freeze-dried powder
$1.00
Elranatamab (ELREXFIO®) is a BCMA-CD3 bispecific antibody used in multiple myeloma research. Supplied as a 76?mg/1.9?mL single-dose vial, manufactured by Pfizer. Approved by FDA (Aug?2023) and EMA (Dec?2023). Ideal for oncology, immunotherapy, and T?cell engager studies.
?? For laboratory research use only – Not for human consumption or therapeutic use.
描述
Elranatamab Injection Description
Product name: Enatumab injection (ELREXFIO)
Packaging specification: 76mg (1.9ml) ? Product dosage form: injection ? Packaging unit: bottle/box
Approval number: National Medicine Standard SJ20250011 ? Drug code: 86978718001636
Manufacturer: Pharmacia & Upjohn Company LLC, USA
ELREXFIO® (elranatamab-bcmm) is a next-generation bispecific T-cell engager antibody that binds to BCMA on malignant plasma cells and CD3 on T cells, initiating targeted cytolysis of multiple myeloma cells?. It is produced using recombinant CHO cells and consists of a four-chain IgG2?a structure with a molecular weight ~148.5?kDa
Supplied as a clear to slightly opalescent 40?mg/mL solution, each 1.9?mL vial contains 76?mg elranatamab, with stabilizers such as histidine, sucrose, and polysorbate 80; pH ~5.8?
ELREXFIO® received accelerated FDA approval in August 2023 for relapsed/refractory multiple myeloma and conditional EU approval in December 2023? It’s also approved in Japan (May 2024), Canada, Australia, Switzerland, and several countries under Project Orbis?
? Product Specifications
| Specification | Details |
|---|---|
| Active Ingredient | Elranatamab?bcmm (ELREXFIO®) |
| Strength & Concentration | 76?mg in 1.9?mL vial (40?mg/mL) |
| Vial Count | Single-dose vial |
| Formulation | Sterile, preservative?free liquid |
| Manufacturer | Pfizer (Pharmacia & Upjohn) |
| Approval | FDA (Aug 2023), EMA (Dec 2023), NMPA equivalent pending |
| Container | Clear glass vial with stopper |
| Appearance | Clear to pale brown / opalescent solution |
| Storage | 2–8?°C; protect from light; do not freeze |
| Shelf Life | As labeled (typically 24 months) |
| Administration | Subcutaneous research use |
? Clinical & Pharmacological Profile
-
Mechanism: Dual-targeted CD3/BCMA binding triggers T?cell cytotoxicity against myeloma cells?.
-
Pharmacokinetics: Steady-state levels at ~76?mg weekly; bioavailability ~56%; Tmax ~7 days after subcutaneous administration?.
-
Half-life: ~22 days at 76?mg dose; Vd ~7.8?L?.
-
Adverse Events: Common toxicity includes cytokine release syndrome (CRS, ~58%), fatigue (~43%), injection-site reactions (~37%), infections, neurotoxicity (ICANS), cytopenias, and GI symptoms?.
-
Risk Management: Administered via step-up dosing and premedication (acetaminophen, dexamethasone, diphenhydramine); hospitalization recommended during initial doses?
-
Regulation: Available under REMS programs due to serious CRS/ICANS risks?drugs.com+2pfizer.com+2elrexfio.pfizerpro.com+2.
? Why Choose ELREXFIO?
-
First-in-class bispecific T-cell engager for BCMA+ myeloma
-
Backed by global regulatory approvals and clinical data
-
Packaged in single-dose vials for precise dosing
-
Strong relevance for immuno-oncology and T-cell research
-
Blinatumomab (CD19-CD3 bispecific)
-
CAR-T cell therapies targeting BCMA
-
Checkpoint inhibitors (e.g., pembrolizumab)
-
Combination agents (e.g. CDK4/6 or IMiD compounds)
? Summary
Elranatamab (ELREXFIO®) is a robust bispecific antibody targeting BCMA and CD3, specifically designed for multiple myeloma and T-cell engagement research. With approved global backing and high-impact use in immunotherapy studies, it’s a valuable addition to any oncology research catalog.
?? For laboratory research or analytical use only — not for human consumption or therapeutic use.
其他信息
| 重量 | 1.1 公斤 |
|---|---|
| 尺寸 | 18 × 16 × 18 厘米 |
Elranatamab Injection 76?mg/1.9?mL/Freeze-dried powder 有 1 个评价
相关产品
-
Doxorubicin Liposome Injection (YiBeiShuang®) – 10?mL:20?mg Vial Wholesale price comparison
YiBeiShuang® is a liposomal formulation of doxorubicin, offering enhanced circulation time and reduced cardiotoxicity compared to the traditional form. Supplied as 20?mg per 10?mL vial, it is strictly for laboratory research use only—not for clinical or human application.?Please consult the staff for other purposes? $2.00 -
Pamidronate Disodium Injection 15?mg × 10 Vials Price comparison
High-purity Pamidronate Disodium 15?mg injectable solution, 10 vials per box. Manufactured by Chengdu Tiantai Shan Pharmaceutical Co., Ltd., it’s a nitrogen-containing bisphosphonate ideal for bone metabolism, osteoporosis, and oncology research.
?? For laboratory research purposes only – Not for human consumption or therapeutic use. $1.00 -
Cetuximab NO1 Injection 100?mg/50?mL (Datalai) by Kelun Botai | EGFR?Targeted Biologic | Price comparison
Cetuximab NO1 Injection, 100?mg in 50?mL vial, is a biosimilar developed by Sichuan Kelun Botai Biopharma, branded as Datalai®. Approved in China (NMPA S20250006), this EGFR-targeting monoclonal antibody is ideal for laboratory or analytical research in oncology.
?? For laboratory research use only – Not for human consumption or therapeutic use. $1.00 -
Abiraterone Acetate Tablets (Hengrui) – 250?mg × 120 Tablets per Bottle Price comparison
Abiraterone acetate is a potent CYP17A1 inhibitor used clinically to suppress androgen synthesis in prostate cancer. Manufactured by Chengdu Shengdi Pharmaceutical Co., Ltd., with China NMPA approval under H20193205 (product code: 86980435000069). This product is for laboratory research and development use only—not for clinical or therapeutic use. $2.00
jmilbur –
The package was received intact, thank you